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accumulation at the lesion edge be detected by 7 T mag-
netic resonance imaging (MRI), and (4) if lesions with 
rims enlarge over time in vivo, when compared to lesions 
without rims. Double-hemispheric brain sections of 28 
MS cases were stained for iron, myelin, and microglia/
macrophages. Prior to histology, 4 of these 28 cases were 
imaged at 7 T using post-mortem susceptibility-weighted 
imaging. In vivo, seven MS patients underwent annual neu-
rological examinations and 7 T MRI for 3.5 years, using a 
fluid attenuated inversion recovery/susceptibility-weighted 
imaging fusion sequence. Pathologically, we found iron 
rims around slowly expanding and some inactive lesions 
but hardly around remyelinated shadow plaques. Iron in 
rims was mainly present in microglia/macrophages with a 
pro-inflammatory activation status, but only very rarely in 
astrocytes. Histological validation of post-mortem suscep-
tibility-weighted imaging revealed a quantitative threshold 
of iron-laden microglia when a rim was visible. Slowly 
expanding lesions significantly exceeded this threshold, 
when compared with inactive lesions (p = 0.003). We show 
for the first time that rim lesions significantly expanded 
in vivo after 3.5 years, compared to lesions without rims 
(p = 0.003). Thus, slow expansion of MS lesions with rims, 
which reflects chronic lesion activity, may, in the future, 
become an MRI marker for disease activity in MS.
Keywords Multiple sclerosis · Iron rim · Phase · 7 T MRI · 
SWI
Introduction
Multiple sclerosis (MS) is a chronic disease of the central 
nervous system (CNS) associated with focal inflammatory 
demyelinating lesions in the white and grey matter [14]. 
Abstract In multiple sclerosis (MS), iron accumulates 
inside activated microglia/macrophages at edges of some 
chronic demyelinated lesions, forming rims. In suscepti-
bility-based magnetic resonance imaging at 7 T, iron-laden 
microglia/macrophages induce a rim of decreased signal at 
lesion edges and have been associated with slowly expand-
ing lesions. We aimed to determine (1) what lesion types 
and stages are associated with iron accumulation at their 
edges, (2) what cells at the lesion edges accumulate iron 
and what is their activation status, (3) how reliably can iron 
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Some lesions remyelinate early after the demyelinating event 
[16] and evolve into remyelinated shadow plaques, which 
protect against axonal degeneration [23]. Other lesions 
remain chronically demyelinated. Chronic demyelination 
fosters persistent low-degree neurodegeneration in the form 
of axonal transections [24]. A subset of lesions with inactive 
demyelinated centers maintains continuous myelin break-
down at the edge, which has led to the pathological concept 
of the slowly expanding lesion [36]. Pathologically, the edge 
of slowly expanding lesions is featured by a rim of acti-
vated microglia/macrophages harboring occasional myelin 
degradation products [15], few T cells [14, 36], and a consid-
erable amount of axonal transections [15].
MS typically starts with relapsing-remitting course 
which progresses into secondary progression in 70% of 
patients. About 10% of patients begin the disease with a 
primary progressive course [32]. The common clinical fea-
ture of progressive MS is a continuous neurological decline 
in the absence of new and contrast-enhancing lesions and 
clinical relapses. There is currently no approved treat-
ment to reduce disability accrual in progressive MS, 
which is partly due to our incomplete understanding of the 
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pathobiological mechanisms underlying progression [32]. 
In a pathological survey on 2,476 WM plaques, slowly 
expanding lesions were predominantly found in progressive 
MS [15] and were suggested to indicate progressive disease 
activity [15, 36]. Focal T-cell-mediated CNS inflammation 
[4] causing relapses seems to differ from the typical micro-
glia-mediated wide-spread inflammation that features pro-
gressive MS [26]. Mitochondrial DNA deletions, oxidative 
stress [20], and iron accumulation and its liberation during 
demyelination [21] are thought to be key factors of neuro-
degeneration in progressive MS [28].
Iron accumulation has been described within microglia/
macrophages at the edges of slowly expanding [5, 21] and 
some inactive lesions, but was not observed around shadow 
plaques [21]. Questions remain whether iron accumulation 
surrounds other lesion types, whether it differs between 
slowly expanding and inactive lesions, and whether it is, 
indeed, absent from edges of shadow plaques. Based on 
proper pathological characterization, edge-related iron 
accumulation might, therefore, separate expanding non-
remyelinating lesions [3] from those with increased remy-
elination probability, and ultimately become a useful imag-
ing biomarker for disease activity in stages of MS, where 
contrast enhancement of lesions is rare or absent.
Magnetic resonance imaging (MRI) and post-mortem 
studies showed that edge-related iron accumulation is cap-
tured by a rim-shaped signal around chronic WM lesions 
when using phase [3, 7, 22, 30, 39], susceptibility-weighted 
imaging (SWI) [18], multi-echo gradient echo R2* [40], or 
quantitative susceptibility mapping (QSM) [10, 12]. These 
rims were seen in patients with either relapsing-remitting 
or secondary progressive MS [30, 40], but were absent 
from supratentorial neuromyelitis optica (NMO) lesions, 
which render iron rims potentially helpful for distinction 
between MS and NMO lesions [10]. Longitudinal analy-
ses of persistent rim lesions in MS thus far showed lack of 
expansion over 2.5 years [7] or slight shrinkage within the 
first 12 months after gadolinium enhancement resolution 
[3], challenging the notion that iron rims surround slowly 
expanding lesions in vivo.
To gain knowledge on the pathological and in vivo fea-
tures of rim lesions, we examined the association between 
rim-shaped iron accumulation at the edges and the patho-
logical stages of lesions in a sample of 28 post-mortem MS 
cases. We then examined whether lesions encircled by a 
rim-shaped signal in SWI are more likely to expand over 
a period of 3.5 years than those without rims in a prospec-
tive longitudinal study in seven patients with MS using a 
fluid attenuated inversion recovery/SWI fusion sequence 
(FLAIR–SWI) at 7 Tesla (7 T) [2, 11, 17].
Materials and methods
Study design, samples and patients
This study is a collaborative project between the Medical 
University in Vienna and the Neurology Department of 
Vanderbilt University, Nashville, TN.
The post-mortem study was performed on two partly 
overlapping samples of 32 MS cases in total, denoted as 
first and second samples. The first sample (28 cases) served 
for global characterization of MS WM lesions, their activity 
state, CD68 expression (microglia/macrophages), and iron 
accumulation (Figs. 1, 2, 4, 5). It consisted of double-hem-
ispheric or large sections. Thirteen cases were provided by 
the University of Vanderbilt which received them from the 
MS Society Tissue Bank (n = 12) and the Rocky Mountain 
MS Center, Colorado, USA (n = 1). Two cases were col-
lected at the Institute of Neurology, Medical University of 
Vienna, Austria, and thirteen were from the archive at the 
Center for Brain Research, Medical University of Vienna, 
Austria. For the first sample, clinical data and numbers of 
WM lesions per case are provided in Table 1. The second 
sample (10 cases) served for the characterization of the 
inflammatory activation status of iron-laden microglia/
macrophages and iron accumulation in astrocytes within 
Fig. 1  Iron-related pathology of slowly expanding and inactive 
lesions as well as shadow plaques. Rim-like iron accumulation was 
observed around a subset of demyelinated WM lesions but hardly 
around shadow plaques. a, b Hemispheric sections of the tempo-
ral lobe of SPMS case 13, stained for myelin (a, blue) and iron (b, 
brown), show several WM lesions. Black arrows/arrowheads indicate 
slowly expanding lesions, red arrows/arrowheads indicate shadow 
plaques, and orange arrowheads indicate an inactive lesion. One 
slowly expanding iron rim lesion is indicated by a black arrow, mag-
nified in c, f, and i. Red arrow indicates the edge of a shadow plaque, 
magnified in e, h, and k. The micrographs depict a slowly expanding 
lesion from SPMS case 13, an inactive lesion from SPMS case 18, 
and a shadow plaque from case 13. c–k The horizontal lesion edges 
divide micrographs into myelinated WM (top half) and lesion (bot‑
tom half). c Slowly expanding edge is characterized by intracellular 
LFB-positive myelin degradation products (arrows, inset). f Micro-
glia/macrophages at the edge display activated morphology (arrows, 
inset) and are reduced in the center. i Iron rim is formed by iron-laden 
microglia/macrophages, which frequently shows dystrophic morphol-
ogy, such as process swellings and buddings (arrows, inset). d This 
inactive edge contains macrophages with intracellular lipofuscin 
lipids (arrows, inset, arrowheads), suggesting remote demyelinat-
ing activity of the lesion. g Fewer microglia/macrophages (arrows, 
inset) at the edge, when compared with f, and loss of microglia/
macrophages in the center. j Few iron-laden microglia/macrophages 
at this inactive edge, while iron content in individual macrophages 
(arrows, inset) is comparable to levels observed at slowly expand-
ing edges. e No lipid-laden macrophages but corpora amylacea (red 
arrows, inset, red arrowheads) are found at this shadow plaque edge. 
h Maintained microglia/macrophage density (arrows, inset) across 
the shadow plaque edge and center, which contrasts microglia loss in 
chronically demyelinated centers. k No edge-contouring iron accu-
mulation around this shadow plaque. Low iron content is observed in 
few cells (arrows, inset). Scale bars 200 µm; inset scale bars 20 µm
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Fig. 2  Quantitative pathological data of the first sample. Optical den-
sities (area fraction) of CD68+ microglia/macrophages (a) and total 
non-heme iron (b) as well as manually counted iron-laden cells with 
microglia or macrophage morphology (c) within an area of 0.43 mm2. 
Hashes indicate significant differences compared with NAWM 
(#: p < 0.05, ##: p < 0.01). Data represent case-based averages of dif-
ferent lesion types. Numbers in brackets at the bottom indicate num-
bers of multiple sclerosis cases and data points contributing to the 
boxplots and statistical tests
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iron rims (Fig. 3, supplementary Fig. 1). The second sam-
ple consisted of 10 cases, 6 cases from the first sample, and 
4 additional cases from the archive at the Center for Brain 
Research, Vienna (Table 2).
For the in vivo study, ten patients with MS [35] were 
consecutively enrolled. Patients fulfilled the following 
inclusion criteria: age >18 years, expanded disability status 
scale (EDSS) ≤6.5 [25], no steroid therapy during the last 
3 months, and no contraindication for 7 T MRI.
They underwent neurological examinations and brain 
MRIs at the following timepoints: study entry or baseline, 
years 1, 2, and 3.5. Patients’ demographic and clinical data 
at the time of the study entry are given in Table 3.
Neuropathology
The first sample (Table 1) consisted of 31 formalin-fixed 
paraffin-embedded tissue blocks comprising double-
hemispheric (n = 24) and large (n = 7, tissue size from 
5 × 5 × 1 cm up to one hemisphere) blocks. For four cases 
(MS 2, 13, 26, 27), only large but no double-hemispheric 
blocks were available. For three cases (MS 6, 10, and 26), 
Table 1  Demographics and clinical characteristics of the first sample of pathological MS cases
A active, A/I active/inactive, AMS acute MS, f female, I inactive, m male, n.a. not available, NAWM normal appearing white matter, PMS progres-
sive MS, PPMS primary progressive MS, PR partially remyelinated, RRMS relapsing-remitting MS, SD standard deviation, SEL slowly expand-
ing lesion, SP shadow plaque, SPMS secondary progressive MS, yrs years
a Case included for sequence validation
Case ID Age at death (years) Sex (f/m) Disease duration 
(years)
Disease course Lesion characterization Analyzed/iron rim 
lesions: n/n (%)
1 35 m 0.13 AMS 3 A 3/0 (0)
2 40 f 10 RRMS 3 A 3/0 (0)
3 60 f 41 RRMS 1 PR 1/0 (0)
4 69 m 43 RRMS 1 SP 1/0 (0)
5 31 m 11 SPMS 1 A, 2 A/I, 1 SP 4/0 (0)
6a 34 m 10 SPMS 2 A/I, 7 SEL, 4 SP 13/9 (69)
7 43 m 16 SPMS 5 SEL, 3 I 8/3 (38)
8 45 f 20 SPMS 2 SEL, 6 I, 1PR, 3 SP 12/0 (0)
9 46 f 22 SPMS 1 A/I, 1 SEL, 9 I, 1 PR 12/1 (8)
10a 46 f 37 SPMS 2 SEL, 3 I, 10 PR,  
17 SP
32/4 (12)
11 55 m 31 SPMS 13 SP 13/0 (0)
12 56 m 31 SPMS 3 A/I, 1 I 4/2 (50)
13 61 f 33 SPMS 2 SEL, 1 I, 2 SP 5/1 (20)
14 62 f 26 SPMS 1 A/I, 3 I, 2 SP 6/0 (0)
15 66 m 51 SPMS 2 PR, 4 SP 6/2 (33)
16 71 f 35 SPMS 2 I, 1 SP 3/1 (33)
17 71 m 46 SPMS 1 A/I, 1 I, 3 PR 5/1 (20)
18 72 f 33 SPMS 1 I 1/0 (0)
19 74 f 48 SPMS 7 I 7/5 (71)
20 79 f 48 SPMS 2 SP 2/0 (0)
21 83 f 47 SPMS 3 I 3/1 (33)
22 88 f 30 SPMS 1 SP 1/0 (0)
23 88 f 36 SPMS 1 PR, 1 SP 2/0 (0)
24 90 f 33 SPMS No lesion only NAWM
25 55 f 5 PPMS 3 I, 14 SP 17/1 (6)
26a 62 m 12 PPMS 2 SEL 2/1 (50)
27a 67 m 7.25 PPMS 3 SEL 3/1 (33)
28 n.a. f n.a. n.a. 6 I, 8 SP 14/2 (14)
All 61.07 ± 16.77 
(mean ± SD)
17/11 (f/m) 28.24 ± 14.75 
(mean ± SD)
3/23 (RRMS/PMS) 7 A, 10 A/I, 24 SEL,  
49 I, 19 PR, 74 SP
183/35 (19)
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Fig. 3  Activation status of iron-laden microglia/macrophages and 
presence of iron-laden astrocytes in slowly expanding lesions of the 
second sample. (a, b) Many microglia/macrophages are iron-laden 
in this slowly expanding iron rim region, and virtually all of them 
express the pro-inflammatory markers CD86 (a) and p22phox (b). 
(d, e) In another region of the same rim with few iron-laden cells, 
still many microglia/macrophages express CD86 (d) and p22phox 
(e). (c) Only few microglia/macrophages were anti-inflammatory and 
CD206-positive. Most of them were located in perivascular spaces, 
and only a minority of CD206-positive cells was iron-laden (f). (g) 
Slowly expanding lesion is visible in the myelin (PLP) staining with a 
sharply demarcated border. (h) Adjacent section stained for iron. The 
border of this iron rim lesion is outlined by a dashed black line. Two 
black arrows indicate focal perivascular iron accumulation within the 
lesion core. The region indicated by the upper arrow is magnified in 
k and l. (i) Iron-laden astrocytes in the iron rim were sparse (arrows, 
inset) and showed weaker iron reactivity, when compared with sur-
rounding microglia/macrophages. (j) Rare astrocytic iron accumula-
tion in the rim was confirmed with double-labeling with GFAP (astro-
cyte marker). (k) Astrocyte (arrow, inset) with contact to a vessel wall 
shows moderate iron accumulation. Many iron-laden astrocytes are 
observed in this region of perivascular iron accumulation within the 
lesion. (l) Confirmation of astrocytic iron with double-labeling. The 
same region as k. Scale bars 100 µm (a–f, i), 2 mm (g, h), 50 µm 
(j–l); inset scale bars 20 µm
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Table 2  Demographics 
and clinical characteristics 
of the second sample of 
pathological MS cases, used for 
characterization of iron-laden 
microglia/macrophages and 
astrocytes
f female, m male, PMS progressive MS, PPMS primary progressive MS, SD standard deviation, SPMS sec-
ondary progressive MS, yrs years
a Case also included in the MS sample (n = 28) shown in Table 1
Case ID Age at death (yrs) Sex (f/m) Disease duration (years) Disease course
6a 34 m 10 SPMS
10a 46 f 37 SPMS
12a 56 m 31 SPMS
13a 61 f 33 SPMS
26a 62 m 12 PPMS
27a 67 m 7.25 PPMS
29 41 m 11.4 SPMS
30 53 f 20.1 SPMS
31 76 m 31 SPMS
32 53 m 14 PPMS
All 54.90 ± 12.45 
(mean ± SD)
3:7 (f:m) 20.68 ± 11.21  
(mean ± SD)
10 PMS
Table 3  Demographics and clinical characteristics of the patients included in the in vivo study
EDSS expanded disability status scale, excl. excluded, f female, FU follow-up, FTY fingolimod, GA glatiramer acetate, INF interferon, m male, 
n.a. not applicable, NTZ natalizumab, RRMS relapsing-remitting multiple sclerosis, SD standard deviation, SPMS secondary progressive multiple 
sclerosis, yrs years, % percentage of discrete lesions that have a rim
a Patient contributed to longitudinal lesion volume data
b At timepoint of study initiation 2010







n//n/n (% rim 
of discrete 
lesions)
Baseline 1-yr FU 2-yr FU 3.5-yr FU
1a 21 f 3 RRMS 0 0 1.0 n.a. 40//5/2 (40)
No No GA –
2a 27 m 7 RRMS 1.5 3.0 2.5 2.5 23//8/6 (75)
INF beta-1A INF beta-1A INF beta-1A INF beta-1A
3a 28 f 3 RRMS 1.0 1.0 1.0 1.0 14//6/2 (33)
INF beta-1A FTY FTY FTY
4a 29 f 5 RRMS 2.0 2.0 2.0 2.5 29//16/11 (69)
GA GA GA GA
5a 36 m 3.5 RRMS 2.0 1.5 2.0 2.5 24//5/2 (40)
INF beta-1A FTY FTY FTY
6a 52 f 6 RRMS 3.0 4.5 5.5 5.5 37//7/3 (43)
GA NTZ NTZ NTZ
7 52 f 25 SPMS 6.5 6.5 Excl. Excl. n.a.//n.a./n.a.
INF beta-1A INF beta-1A – –
8a 53 m 28 SPMS 6.5 6.5 6.5 7.0 16//5/2 (40)
No No No No
9 60 f 20 SPMS 6.5 Excl. Excl. Excl. n.a.//n.a./n.a.
INF beta-1b – – –
10 62 f 37 SPMS 6.0 6.0 6.0 6.5 34//0/0 (0)
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two blocks per case were included. The second sample con-
sisted of ten blocks of ten cases. Three large blocks of the 
first sample were also included in the second sample and 
seven were additional routine blocks used for the second 
sample only. Consecutive double-hemispheric or large sec-
tions were cut with a tetrander microtome at a thickness 
of 10 µm and mounted on glass slides. Routine sections 
were cut at a thickness of 5 microns and mounted on glass 
slides. Sections were stained for hematoxylin and eosin to 
exclude confounding pathologies. Luxol fast blue-periodic 
acid Schiff (LFB-PAS) myelin staining was performed for 
assessment of WM lesions, including demyelinating activ-
ity and remyelination (Fig. 1a). DAB-enhanced Turnbull 
blue staining for di- and trivalent (total) non-heme iron 
was done as previously described [21, 29]. Immunohisto-
chemistry for the myelin protein proteolipid protein (PLP) 
and the lysosomal glycoprotein CD68, indicating activated 
microglia/macrophages, was performed as described [21]. 
Sources, pretreatments and dilutions of primary antibod-
ies are listed in Table 4. CD68 stainings were not coun-
terstained to facilitate subsequent digital quantification. 
Double-labeling of iron with immunohistochemistry for 
the microglia/macrophage activation markers p22phox, 
CD86, CD206, and the astrocyte marker GFAP (Fig. 3) 
was performed on the second sample. Double-labeling of 
iron with CD68 (Fig. 4n) was performed on MS 26. For 
double-labelings, Turnbull blue staining was performed 
as described, but developed with aminoethyl carbazole 
(p22phox, CD86, CD206, and CD68) under microscopic 
control [21]. For double-labeling of iron with the astro-
cyte marker GFAP (Fig. 3), Turnbull staining was devel-
oped with DAB according to the protocol used for single 
labelings. After washing in aqua bidestillata, the sections 
were steamed for antigen retrieval (Table 4). Blocking of 
non-specific antibody binding was followed by incubation 
of the primary antibodies overnight at 4 °C. Appropriate 
secondary antibodies were applied for 1 h at room tem-
perature. Secondary antibodies were either biotinylated (for 
p22phox, CD86, CD206, or GFAP) or directly conjugated 
to alkaline phosphatase (for CD68). If a biotinylated sec-
ondary antibody was used, sections were further incubated 
with avidin-conjugated alkaline phosphatase for 1 h at 
room temperature. The sections were developed with Fast 
Blue substrate (Sigma) at 37 °C. 
Histopathological lesion characterization
Characterization of WM lesions was performed as 
described [9, 15]. Active lesions harbored degradation 
products reactive for LFB and PLP inside macrophages 
[9] throughout the lesion. Active/inactive lesions showed 
a confined presence of macrophages with LFB- and PLP-
reactive degradation products at the lesion edge (active 
zones). In this type of lesions, numerous predominantly 
perivascular macrophages containing PAS-positive lipids 
[27] were seen in the lesion cores, suggesting more remote 
demyelinating activity (inactive zones). Slowly expanding 
and inactive lesions showed sharply demarcated borders 
[15], inactive demyelinated centers without any degrada-
tion products [15], and occasional LFB-positive myelin 
degradation products in microglia or macrophages at edges 
of slowly expanding but not inactive lesions (Fig. 1). 
Remyelinated shadow plaques were identified by their 
sharply demarcated homogeneous reduction of LFB stain-
ing intensity [8] and were classified as shadow plaques if 
the whole lesional area was remyelinated. Partially remy-
elinated lesions showed areas of remyelination and com-
plete demyelination [8].
Histological quantification
Digital color (RGB) images sized 0.76 × 0.57 mm 
(0.43 mm2) were taken at constant illumination and micro-
scope conditions [21] from different ROIs in the slides 
stained for iron and CD68. Three ROIs, at least 1 cm away 
from any MS lesion, represented the NAWM. A mean value 
across the three NAWM-ROIs was computed for the analy-
ses. From each WM lesion, three images at the lesion edge 
and one in the lesion center were taken. For both iron and 
CD68 stainings, the three edge images were placed with 
regard to the most pronounced, least pronounced, and in-
between CD68 edge expression, regardless of presence 
Table 4  Primary antibodies used for immunohistochemistry
CD cluster of differentiation, DL double-labeling, EDTA ethylenediaminetetraacetic acid, GFAP glial fibrillary acidic protein, Mc monoclonal, 
Pc polyclonal, PLP proteolipid protein, SL single-labeling
Target Antibody type Dilution Antigen retrieval Source (product number) Protocol
PLP Mc mouse 1:1000 60 min steaming with EDTA, pH 8.5 AbD Serotec, Oxford, UK (MCA839G) SL
CD68 Mc mouse 1:100 60 min steaming with EDTA, pH 9 Dako, Carpinteria, CA (M0814) SL, DL
CD86 Pc goat 1:50 60 min steaming with EDTA, pH 9 R&D Systems (AF-141-NA) DL
CD206 Mc mouse 1:200 45 min steaming with EDTA, pH 9 Abcam (ab 117644) DL
GFAP Pc rabbit 1:3000 45 min steaming with EDTA, pH 8.5 Thermo Scientific, Waltham MA (MS-1376-P1) DL
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of iron. One center image was placed in the lesion center. 
Images were quantified using custom-written plugins for 
the ImageJ version 1.43r, which have been used before 
[21]. After grey-scale conversion of the images, the plugins 
apply a constant threshold after subtracting the mean grey 
value from the image, yielding a numerical estimation of 
CD68 and iron staining (area fraction) (Fig. 2a, b). On the 
RGB images of the iron stainings, cells with strong iron 
accumulation displaying microglia or macrophage mor-
phology were manually counted (Fig. 2c). Values of the 
three edge images and data of multiple lesions of a lesion 
type per case were averaged to finally represent each lesion 
type per ROI per case with one data point for plotting and 
statistical testing (case-based averages) (Fig. 2). In the 
second sample, the p22phox-iron and CD206-iron double-
labelings (Fig. 3) were quantified by manual counting of 
p22phox or CD206 single-positive cells, iron single-pos-
itive cells (on p22phox-iron stainings only), and double-
positive cells (supplementary Fig. 2). Total p22phox or 
CD206-positive cells were determined by adding p22phox 
or CD206 single-positive cells to the double-labeled cells. 
For these quantifications, two ROIs were chosen in the 
edges of rim lesions: one ROI with the lowest, and one ROI 




Prior to paraffin embedding, four large formalin-fixed tis-
sue samples (MS 6, 10, 26, and 27) were imaged using 
a 7 T whole body MR system (Magnetom® Siemens 
Healthcare, Erlangen, Germany) equipped with a 72 mm 
volume coil (RAPID® Biomedical, Würzburg, Ger-
many). Samples were placed in a cylindrical, custom-
fabricated polyvinyl chloride container and immersed 
in perfluorinated fluid (Galden® SV 80, Solvay Spe-
cialty Polymers, Milan, Italy). A three-dimensional 
(3D) SWI sequence was obtained using the following 
parameters: echo time (TE) = 15 ms, repetition time 
(TR) = 24 ms, in plane image matrix = 576 × 576 pix-
els, resolution = 0.14 × 0.14 × 0.35 mm, slices = 120–
144 (sample-dependent), acquisition time (one meas-
urement) = 27:39–33:18 min, and averages = 6. Phase 
images were filtered using Homodyne filtering [31]. SWI 
images were created by applying four multiplications of a 
positive phase mask to the SWI magnitude data [17, 19]. 
T2-weighted data were acquired using a two-dimensional 
(2D) turbo spin echo (TSE) sequence with TE = 34 ms, 
TR = 5370 ms, resolution = 0.11 × 0.11 × 0.6 mm, 60 
slices, acquisition time (one measurement) = 10:50 min, 
and averages = 5.
Lesion identification and analysis
WM lesions were identified on T2-weighted TSE and SWI 
images (Fig. 4). A threshold for the number of iron-laden 
microglia/macrophages inducing a dark SWI rim was 
determined by taking 10 to 16 images of iron stainings 
per lesion along the edges (54 ROIs in total) and count-
ing of iron-laden microglia/macrophages. On the matched 
SWI scans, the presence or absence of a dark edge-related 
SWI signal was outlined to determine whether a pathologi-
cal ROI corresponded to a hypointense SWI signal or not. 
This evaluation was performed in a blinded manner by 
two different investigators. The threshold was set to have 
equal numbers of data points (i.e., 2) above the threshold 
in “no dark SWI signal” ROIs and below it in “dark SWI 
signal” ROIs (Fig. 5a). Microglia/macrophage countings 
in all lesion edges were plotted together with this thresh-
old (Fig. 5b). Slowly expanding and inactive lesion edge 
data were dichotomized using this threshold for Chi-square 
analysis. Here, only one edge image of the iron staining per 
lesion corresponding to the maximum CD68 expression as 




Imaging was performed on the same 7 T MR system, using 
a 24-channel coil (Nova Medical, Wilmington, USA) first 
and a 32-channel radio frequency (RF) coil (Nova Medical, 
Wilmington, USA), as it became available. FLAIR images 
were acquired using a TSE sequence with variable flip-
angle echo trains. Detailed information on pulse sequence 
parameters has been published previously [11]. SWI data 
were acquired using a 3D fully first-order flow-com-
pensated SWI sequence with TE = 25 ms, TR = 38 ms, 
image matrix = 704 × 704, slices = 96, parallel imag-
ing factor = 2, acquisition time = 13:56 min, and resolu-
tion = 0.3 × 0.3 × 1.2 mm. Phase filtering and SWI image 
processing was performed by the manufacture. The FLAIR 
sequence was then combined with the filtered SWI phase 
data (vendor-provided) as described previously, referred to 
as FLAIR–SWI contrast [17].
T1-weighted data were acquired using an magnetiza-
tion-prepared rapid gradient echo (MP-RAGE) sequence 
with the following parameters: TR/inversion time (TI)/
TE = 3800/1700/3.55 ms, image matrix = 320 × 320; 
resolution = 0.75 × 0.72 × 0.7 mm; slices = 208; and 
parallel imaging factor = 2; acquisition time = 10:29 min. 
Post-contrast images (acquired only at the first year of 
follow-up) were obtained 10 min after the injection of the 
contrast agent gadobenate dimeglumine (Multihance®, 
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Bracco Imaging S.P.A., Colleretto, Italy), administered at 
the dose of 0.2 ml/kg body weight.
Lesion identification and quantification
Lesions detected in the frontal, parietal, and occipital 
lobes as well as the superior parts of the temporal lobes 
of the supratentorial brain were included in the analysis. 
Rim and non-rim WM lesions were identified at baseline 
and lesion volumes quantified annually on the FLAIR–
SWI images by a neurologist specialized in MS (ADB), 
who was supervised by a certified radiologist (ST). Rim 
lesions were defined as discrete hyperintense WM lesions 
in FLAIR images entirely or partially surrounded by a rim 
of decreased signal on FLAIR–SWI. The rim was required 
to be seen on at least three contiguous slices. We also iden-
tified discrete hyperintense lesions without a rim at their 
edges and separated them from confluent WM lesions 
without a rim. Rim lesions and discrete but not confluent 
non-rim lesions were manually traced on the FLAIR–SWI 
images and volumes computed using Display, part of the 
MINC toolbox (http://packages.bic.mni.mcgill.ca). Fifteen 
randomly selected rim or non-rim lesion volumes were seg-
mented twice to determine the intraclass correlation (ICC) 
of the volume measurements.
Statistical analysis
Data were analyzed using IBM SPSS® Statistics for Win-
dows Version 20. Normally distributed metric data are 
described using mean ± standard deviation (SD). In case 
of skewed (histological) data, boxplots indicating medians, 
interquartile ranges (IQR), 1.5 × IQR (whiskers), and out-
liers (circles and stars) are presented. Nominal data are 
described using absolute frequencies and percentages. Due 
to non-normal distribution of histological data, conservative 
non-parametric Kruskal–Wallis and post-hoc Mann–Whit-
ney U tests were used for comparison of regions of interest 
and corrected for multiple comparisons according to Bon-
ferroni–Holm. To test the association between categorical 
variables (i.e., above/below threshold and slowly expand-
ing/inactive lesions), a Chi-square test was performed. A 
mixed-model ANOVA (fixed within-subject factor ‘time’, 
fixed between-subject factor ‘rim/non-rim lesions’, ran-
dom factor ‘patient’) was used to compare changes of 
logarithmically transformed relative volume fraction data. 
An unstructured covariance matrix was applied, because it 
showed the best fit to the data according to the Schwarz’s 
Bayesian Information Criterion (BIC). Other covariance 
matrices tested were Compound Symmetry, Autoregressiv 
1, and a Diagonal Covariance Matrix. For modelling the 
random factor ‘patient’, multiple lesions per patient were 
considered. The reported p values are results of two-sided 




Rim‑like iron accumulation at edges of a subset of WM 
lesions
In the first sample of 28 MS cases with double-hemi-
spheric or large sections, 183 WM MS lesions were found 
(Table 1). 7 lesions from 3 cases were active, 10 from 6 
cases were active/inactive, 24 from 8 cases slowly expand-
ing, 49 from 14 cases inactive, 19 from 7 cases partially 
remyelinated, and 74 from 15 cases were shadow plaques. 
Iron accumulation along some lesion edges formed a com-
plete or incomplete rim (Fig. 1a, b). This was the case in 11 
out of 24 slowly expanding lesions, defined by the presence 
of LFB-positive myelin degradation products in microglia/
macrophages (Fig. 1c, inset). Slowly expanding lesions 
also showed elevated numbers of CD68-positive microglia/
macrophages at the lesion edge (Fig. 1f, inset). Iron was 
mainly present in microglia/macrophages (Fig. 1i). Inac-
tive edges were accompanied by the presence of lipofus-
cin-loaded macrophages (Fig. 1d, inset) on adjacent slides 
stained for LFB-PAS, indicating cessation of demyelinating 
activity months or years prior, while iron was still stored 
in the remaining cells. Density of CD68-positive microglia/
macrophages was lower in inactive (Fig. 1g) than in slowly 
expanding edges (Fig. 1f). Edge-related iron accumulation 
Fig. 4  Post-mortem validation of SWI and underlying phase images 
at 7 T for the sensitive and specific detection of iron rims around MS 
lesions. Left a Slowly expanding rim lesion (red arrows) of PPMS 
case 26 with hypointense portions along the lesion edge around a 
hyperintense lesion center. b Corresponding iron staining confirms 
iron accumulation at the lesion edge (red arrows). c Extent of the 
hyperintense lesion in the T2 image. Black arrows in (d, e, f) high-
light portions of edge-related hyperintense phase and hypointense 
SWI, which correspond to iron accumulation. Red arrows in (d, e, f) 
highlight portions which lack hyperintense phase, hypointense SWI 
and iron accumulation. f The blue rectangle is magnified in (g) and 
shows iron-laden microglia/macrophages, which is confirmed by 
double-labeling with the microglia/macrophage marker CD68 (h). 
Arrows indicate double-labelled microglia/macrophages. i Extent 
of the demyelinated lesion in PLP staining for myelin. Right j inac-
tive lesion (red arrows in j, k) of PPMS case 27 without edge-related 
hypointensities around the hyperintense lesion center. k Correspond-
ing iron staining confirms lack of edge-related iron accumulation. 
l Extent of the hyperintense lesion in the T2 image. Red arrows in 
(m, n, o) indicate lesion edge devoid of hyperintense phase, hypoin-
tense SWI, and iron accumulation. o Black rectangle is magnified in 
(p), showing the absence of iron-loaded microglia/macrophages. q 
Extent of the demyelinated lesion in PLP staining for myelin. Scale 
bars = 100 µm (g, p) and 30 µm (h)
◂
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in microglia/macrophages was observed around 6 out of 49 
inactive lesions (Fig. 1j). The highest density of iron-laden 
microglia/macrophages found at the edge of an inactive 
lesion is shown in supplementary Fig. 1. Fully remyeli-
nated lesions, so called shadow plaques, did not show con-
spicuous changes in CD68-positive cell densities, neither 
in the plaque edge nor in the center (Fig. 1h). Edge-related 
iron accumulation in microglia/macrophages was hardly 
observed around shadow plaques (Fig. 1k). The highest 
density of iron-laden microglia/macrophages found at a 
shadow plaque edge is displayed in supplementary Fig. 1. 
Active lesions did not show iron accumulation at the lesion 
edge (not shown). The majority of MS lesions, regardless 
of lesion type, displayed reduced overall iron load in the 
lesion center, when compared with the periplaque WM 
(Fig. 1).
Iron and microglia/macrophages in NAWM and WM 
lesions
Densities of CD68+ microglia/macrophages across regions 
of NAWM and different lesion subtypes confirmed proper 
region selection for cellular iron densities and countings 
(Fig. 2a, first sample). We observed significantly higher 
CD68 expression at the edges of active (Mann–Whitney U 
test, p = 0.003 after correction for multiple comparisons), 
active/inactive (p = 0.008), and slowly expanding lesions 
(p = 0.01), when compared with NAWM. Conversely, 
inactive edges did not significantly differ from NAWM in 
their level of CD68 expression (p = 1 after correction for 
multiple comparisons). Intracellular iron densities, deter-
mined by digital optical densitometry using the area frac-
tion method in the ImageJ, were significantly different only 
at slowly expanding lesion edges compared with NAWM 
(Fig. 2b) (p = 0.01). Countings of iron-laden microglia/
macrophages revealed a significant elevation of iron-
laden microglia/macrophages both in slowly expanding 
(p = 0.045) and inactive lesion edges (p = 0.004), when 
compared with NAWM (Fig. 2c). No significant increase in 
edge-associated iron was seen in shadow plaques.
Activation status of iron‑laden microglia/macrophages 
at slowly expanding lesion edges
The second sample of 10 MS cases harbored 10 lesions 
(1 lesion per case), all of which were classified as slowly 
expanding. These sections were double-labeled for iron and 
the pro-inflammatory marker p22phox [13], the costimu-
latory molecule CD86 (pro-inflammatory M1 activation), 



































(10) (24) (49) (19)(34) (20)
p < 0.001
(7 () 74)
b p = 0.003*
Fig. 5  Iron-laden microglia/macrophages at edges of WM lesions of 
the first sample. a Establishment of a post-mortem threshold (dashed 
line) for manually counted iron-laden microglia/macrophages to 
induce a dark rim signal in SWI, based on four multiple sclerosis 
cases and four WM lesions with available post-mortem scans. Each 
data point represents one ROI. Numbers in brackets indicate numbers 
of ROIs. b Application of the threshold (dashed line) for the edges of 
all 183 WM lesions indicates that 2/10 active/inactive, 11/24 slowly 
expanding, 6/49 inactive lesions, and 1/74 shadow plaques exceeded 
this threshold. *P value of Chi-square test between slowly expand-
ing and inactive lesion edges which were either below or above the 
threshold. Each data point represents the value of one lesion edge. 
Numbers in brackets indicate numbers of data points and individual 
lesions
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activation) [33] (Fig. 3). The majority of iron-laden micro-
glia/macrophages at slowly expanding edges expressed 
CD86 and p22phox (Fig. 3a, b). However, microglia/mac-
rophages devoid of iron also expressed these molecules in 
slowly expanding edges (Fig. 3d, e). Expression of CD206 
at the lesion edge was generally sparse and predominantly 
found in perivascular macrophages devoid of iron (Fig. 3c). 
Of the few CD206-positive microglia/macrophages, a small 
minority was iron-laden, thus double-positive for CD206/
iron (Fig. 3f). Manual countings of microglia/macrophages 
on sections stained for p22phox/CD206 with iron are dis-
played in supplementary Fig. 2. CD86 expression was very 
similar to p22phox expression at slowly expanding lesion 
edges; therefore, these stainings were not counted. In the 
whole second sample, iron-positive astrocytes were only 
exceptionally found in the iron rims and invariably sur-
rounded by a majority of microglia/macrophages with a 
stronger iron staining (Fig. 3i, j). Six out of ten lesions of 
the second sample displayed focal perivascular iron accu-
mulation in the lesion center (exemplified in Fig. 3h, black 
arrows). Iron-laden astrocytes were more numerous in 
these regions than in the iron rims (Fig. 3k, l).
Hypointensities at lesion rims reflect iron‑laden microglia/
macrophages in post mortem SWI
Post-mortem SWI disclosed four large periventricular MS 
lesions (one lesion per case), two of which are presented in 
Fig. 4. Two lesions were pathologically classified as slowly 
expanding and presented rims of decreased signal on SWI 
(Fig. 4a). These two lesions showed iron rims (Fig. 4b, 
f), which correlated with hyperintense phase (Fig. 4d), 
hypointense SWI (Fig. 4e), and iron-laden microglia/mac-
rophages (Fig. 4g, h). In the other two lesions, which were 
pathologically classified as inactive, no rims of hypoin-
tense SWI (Fig. 4j, n) or hyperintense phase (Fig. 4m) 
were observed. Edge-related iron accumulation was absent 
(Fig. 4k, o), as were iron-laden microglia/macrophages 
(Fig. 4p). Iron-laden microglia/macrophages were counted 
along the edges of these 4 WM lesions in 54 ROIs, which 
were manually stratified into either matching with a dark 
SWI rim or not (Fig. 5a). ROIs matching with a dark SWI 
rim contained significantly more iron-laden microglia/mac-
rophages (p < 0.001), providing a threshold of 47.5 iron-
laden microglia/macrophages per image required to be 
reflected as a dark rim in post-mortem SWI. Applying this 
threshold to the countings in all 183 lesion edges of the first 
sample, we found a significant difference of the likelihood 
of slowly expanding lesions (11/24, 45.8%) versus inac-
tive lesions (6/49, 12.2%) to exceed this threshold (Pear-
son Chi-square = 10.147; p = 0.003) (Fig. 5b). Two active/
inactive, one out of seventy four shadow plaques, and 
none of the seven active or nineteen partially remyelinated 
lesions exceeded this threshold. The single shadow plaque 
edge exceeding the threshold is depicted in supplementary 
Fig. 1.
In vivo study
The 7 T scan was well tolerated by all patients. Two 
patients complained of transient and short-lasting dizzi-
ness upon entering in the scanner. Of all examined MRIs 
obtained after contrast injection, i.e., at year 1, none 
showed enhancing lesions. Data of two patients with sec-
ondary progressive MS were excluded from the analysis 
due to movement artifacts. These two patients also could 
not complete the follow-up because of disability accretion. 
One patient with secondary progressive MS did not present 
any rim lesion and was not included in the lesion volume 
analysis (Patient 10 in Table 3). One patient missed the 
3.5-year follow-up examination due to a newly implanted 
dental brace but was included in the analysis (Patient 1 in 
Table 3). Data from seven patients were thus included into 
longitudinal lesion volumetry.
In vivo incidence of WM lesions and evolution of rim 
lesions
At baseline, we counted 183 WM lesions on the FLAIR–
SWI sequence. In addition, 14 lesions in 5 RRMS patients 
appeared newly within 3.5 years. None of these newly 
appearing lesions displayed rims and none were included 
in the longitudinal volumetric analysis. Of the 183 WM 
lesions present at baseline, 28 (15.3%) were surrounded by 
a rim of decreased signal on SWI, while 24 (13.2%) were 
discrete and did not show a rim. The remaining 131 lesions 
(71.5%) did not show a rim and were confluent, spanning 
over large areas of the brains. Thus, 84.5% of the 155 non-
rim lesions were confluent and not included in the volumet-
ric analysis. 52 lesions (28 rim lesions, 24 discrete non-rim 
lesions) were included in the volumetric analysis. Since 
one patient missed the last follow-up, 47 lesions (26 rim 
lesions, 21 discrete non-rim lesions) were analyzed at last 
follow-up.
Rim lesions were observed in six RRMS and one SPMS 
patient (Table 3). Neither appearance nor disappearance 
of rims was noted during the study period, i.e., all of the 
observed rims were persistent. In two patients, parts of 
two rim lesions expanded over time and coalesced into one 
large lesion. Expansion of the posterior parts of such a rim 
lesion together with fusion of initially separated lesion parts 
is shown in Fig. 6. Rim lesions were significantly larger 
than discrete non-rim lesions at each timepoint (Mann–
Whitney U tests; p = 0.019 at baseline, p = 0.003 at 1- and 
2-year follow-up, p < 0.001 at 3.5-year follow-up). Single 
lesion volumes with data points connected from baseline 
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and last available follow-up are displayed in Fig. 7a (non-
rim lesions) and b (rim lesions). Over 3.5 years, rim lesions 
expanded on average by 29.33%, whereas non-rim lesions 
decreased by 10.04%. The volume developments over 
time were significantly different between rim and non-rim 
lesions (mixed-model ANOVA, factor ‘iron rim*timepoint’, 
F49.552 = 6.746, p = 0.003) (Fig. 7c), also when accounting 
for patients as random factor in the model. Intraclass corre-
lation of 15 lesion volumes measured twice was r = 0.998.
Discussion
We report four key observations in our present study: (1) 
An iron rim at the edge of an MS lesion is predominantly 
seen in slowly expanding lesions, much less frequently in 
inactive lesions, not in active and hardly in remyelinated 
lesions. (2) The iron containing cells in the rim are in their 
vast majority microglia/macrophages with a pro-inflam-
matory activation status, while iron-positive astrocytes are 
sparse or absent. (3) Direct 7 T MRI—pathology correla-
tion shows that the iron rim, defined by pathology, can be 
reliably visualized by magnetic resonance imaging. (4) 
Lesions with an iron rim on average expand very slowly, 
while non-rim lesions show a tendency to shrink. Although 
expansion of rim lesions has already been observed in indi-
vidual MS lesions [2, 3], we have statistically proven this 
expansion for the first time in multiple MS patients and 
lesions. However, it is important to note that some non-
rim lesions expanded and some rim lesions shrinked. Our 
data, therefore, indicate that an observed rim lesion does 
not necessarily expand over time, but has a higher probabil-
ity to do so, when compared with non-rim lesions. Using 
post-mortem pathology-imaging correlations, we con-
firm this rim to be due to the presence of iron inside pro-
inflammatory activated microglia/macrophages [3, 5, 22]. 
In line with pathological [5, 21, 30, 34] and in vivo [3, 39, 
40] studies, this pattern of iron accumulation was restricted 
to edges of chronically demyelinated lesions, not present 
in active lesions [1], and hardly observed in fully remyeli-
nated shadow plaques [21].
Pathologically, we observed the most pronounced iron 
accumulation at the rims of slowly expanding lesions. The 
empirically derived threshold for iron-laden microglia/mac-
rophages sufficient to decrease the signal in post-mortem 
SWI revealed a significant association of slowly expanding 
Fig. 6  Expansion of a rim lesion. Patient 4, a 29-year-old lady with 
relapsing-remitting multiple sclerosis lasting for 5 years, EDSS 2. 
7 T FLAIR–SWI data show several WM hyperintense lesions typical 
for the disease. One large periventricular hyperintense lesion with an 
encircling hypointense rim is indicated by a white rectangle and mag-
nified. Within this lesion, tubular hypointense structures suggestive of 
veins and circumscribed nodular hypointensities are visible. Images 
demonstrate a slow expansion of the posterior parts of this lesion 
over 3.5 years, leading to a fusion of initially separated lesion parts. 
Three contiguous imaging slices (−1, 0, +1) show that expansion 
and fusion are not due to willful slice sampling. Note the global brain 
atrophy of this patient over time, which is evident from the widening 
of the ventricles. BL baseline, FU follow-up, yr year
▸
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lesions with a rim in SWI, when compared with inactive 
lesions. However, translating this threshold to the in vivo 
situation needs to be exerted with caution, given the differ-
ences in imaging resolution and tissue properties between 
in vivo and post-mortem imaging. One explanation for the 
absence of iron rims in classical active lesions could be 
the dynamics of lesion formation. In active lesions, myelin 
fragments are mainly taken up by cells with a macrophage 
phenotype (round, no processes). These are mobile, dis-
perse within the lesion, and finally accumulate in perivas-
cular spaces. Conversely, in slowly expanding lesions, tis-
sue debris is taken up by cells with microglia phenotype 
(branched cells with processes). Microglia may remain sta-
tionary at lesion edges for prolonged time periods, which 
may form the basis for the persistent iron rim. Lack of 
iron accumulation in the vast majority of astrocytes found 
in iron rims could be related to the elevated expression of 
the iron exporter ferroxidase ceruloplasmin in astrocytes at 
edges of MS lesions [21], indicating active iron efflux by 
astrocytes.
Microglia and macrophages in iron rims highly 
expressed the pro-inflammatory markers CD86 and 
p22phox, while anti-inflammatory CD206 (mannose 
receptor) expression was rare and, in line with prior results 
[38], mainly expressed by perivascular macrophages. In 
the mentioned study [38], CD206 in active MS lesions 
was also expressed by 70% of myelin-laden foamy mac-
rophages which expressed M1 markers. Thus, the authors 
proposed an intermediate activation status of the majority 
of macrophages in active MS lesions. This situation is dif-
ferent for edges of slowly expanding lesions, as reported 
here, where the majority of microglia/macrophages show 
a clear pro-inflammatory activation status without CD206 
expression. A similar concept has been proposed by Pitt 
and collaborators [30], who also showed that CD206 
was mainly expressed by lipid-laden macrophages in MS 
lesions, while iron-laden microglia/macrophages at edges 
of lesions did not express CD206. We have addition-
ally shown the expression of pro- and anti-inflammatory 
markers in double-labelings with iron in a sample of ten 
well-characterized slowly expanding lesions. Expression 
of pro-inflammatory markers in microglia/macrophages 
was independent from iron accumulation in these cells 
in our study. Therefore, the iron rim indicates microglia/
macrophages with a pro-inflammatory activation status, 
but iron itself does not seem to induce pro-inflammatory 
activation, as determined by the markers we have included 
(CD86, p22phox). Our interpretation is that pro-inflamma-
tory microglia/macrophages at edges of slowly expanding 
lesions either accumulate iron or not, but iron rims specifi-
cally indicate microglia/macrophages with a pro-inflam-
matory activation status.
Lack of iron rims around the vast majority of shadow 
plaques is particularly informative in comparison with inac-
tive lesions. This feature might indicate that remyelination 
is restricted to lesions which have never undergone a stage 
of edge iron accumulation, because otherwise traces of 
long-standing edge iron in a subset of remyelinated shadow 
plaques would be expected. However, extended follow-up 
studies of rim lesions will be able to investigate whether 
they do not remyelinate.
Our data are in line with another study showing 
lack of remyelination in five lesions of a single pro-
gressive MS autopsy case displaying phase rims and 




































































Fig. 7  Volumetric longitudinal data of non-rim and rim lesions. 
Absolute lesional volumes of non-rim (a) and rim lesions (b) in 
mm3. Data points from baseline and last available follow-up of single 
lesion volumes are plotted on a logarithmic scale. c Logarithmically 
transformed lesion volume changes relative to baseline. Mean val-
ues (circles) are plotted with 95% confidence intervals (bars). After 
3.5 years, rim lesion volumes showed significant expansion over time 
compared with non-rim lesions that on average shrink. *P value indi-
cates significantly different volume developments between rim and 
non-rim lesions (mixed-model ANOVA, factor ‘rim*timepoint’). FU 
follow-up, yr year
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pathologically confirmed iron accumulation [3]. Based 
on in vivo data, the authors conclude from a progres-
sively lower T1 intensity between 3 and 12 months of 
observation seen in 7/10 lesions with persistent phase 
rim versus 7/26 lesions without phase rim that the phase 
rim lesions showed failure of early tissue repair and 
possibly remyelination failure, as opposed to non-rim 
lesions. This is in line with our observation in 74 shadow 
plaques of 15 MS autopsy cases, showing the absence 
of remyelination in iron rim lesions and the absence of 
iron rims in remyelinated lesions. While T2-weighted or 
FLAIR images are unable to separate remyelinated from 
demyelinated lesions [6], SWI could, therefore, help to 
distinguish them.
We do not think that remyelination might explain the 
observed shrinking of hyperintense non-rim lesions in our 
survey, since remyelinated lesions were as T2-hyperintense 
as completely demyelinated lesions in a post-mortem cor-
relation study [6]. Conversely, we ascribe the -10% base-
line volume of non-rim lesions to lesion-specific gliosis 
and neurodegeneration, which leads to tissue retraction and 
shrinkage [28].
The frequency of rims around WM lesions in our in vivo 
data (15.3% of all observed WM lesions) is similar to that 
of another in vivo study, where authors reported 10.1% 
of all MS WM lesions to display a rim indicative of iron 
accumulation [10]. These authors furthermore noted that 
the majority (83.3%) of MS lesions lacking MRI signs sug-
gestive of iron accumulation were ill-defined and showed 
faint margins. In comparison, 84.5% of our non-rim lesions 
were ill-defined and confluent and, therefore, not included 
in volumetric analysis, which is crucially dependent on a 
reliable depiction of the lesion margin.
Rim lesions were significantly larger than non-rim 
lesions at each timepoint, which is in line with other data 
[3]. First, larger size of rim lesions could be the result of 
their expansion together with shrinkage of non-rim lesions 
over time. Second, lesions which are larger at baseline 
could be more likely to end up as slowly expanding. The 
latter possibility is suggested by data from Absinta et al. 
[3]. In this study, newly forming and enhancing lesions, 
which later developed a persistent phase rim, were already 
larger at baseline (timepoint of gadolinium enhancement) 
than lesions which did not develop a persistent phase rim.
Limitations of the study
The main limitation of this study arises from the small 
cohort of MS patients and low number of lesions which 
were manually traced for volumetry in vivo. Future studies 
on larger patient cohorts are, therefore, needed for the rela-
tion between presence of rim lesions and, ultimately, MS 
disease course or severity. Another limitation comes from 
the fact that MS cases, sequence parameters and tissue con-
ditions were not identical between in vivo and post-mortem 
imaging. Therefore, the translation of post-mortem and 
in vivo MRI findings needs to be perceived with caution. 
Furthermore, we could not account for the effect of whole 
brain atrophy on longitudinal lesion volumes in this study, 
since brain volumetry using 7 T MRI is still challenging 
[37].
Conclusions
Our study shows that iron in the brains of patients with 
relapsing or progressive MS accumulates at the edge of 
slowly expanding lesions in microglia/macrophages. There 
it persists for months to years when lesions are slowly 
expanding or when demyelinating activity has ceased. This 
iron deposition is visible by susceptibility-based MRI and 
indicates chronic lesions with pro-inflammatory microglia/
macrophages, complete myelin loss within the rim and 
absence of remyelination. On average, MS lesions with 
iron rims expand slowly, while lesions without iron rims 
show a tendency to decrease in volume. In remyelinated 
lesions, iron rims have hardly been observed, indicating 
that they may impair myelin repair. These data suggest that 
the presence of iron rims in MRI images of MS brains may 
be a sign of progressive tissue injury. Whether iron rims 
may become a paraclinical marker for disease activity or 
prognosis in patients with relapsing and progressive MS, 
has to be determined in future prospective studies.
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